Phase I/II trial of BPX-401 in patients with haematological cancer
Phase of Trial: Phase I/II
Latest Information Update: 09 May 2016
At a glance
- Drugs BPX 401 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bellicum Pharmaceuticals
- 09 May 2016 According to a Bellicum Pharmaceuticals media release, the company plans to initiate the clinical development of BPX-401 in the second half of 2016.
- 17 Mar 2015 New trial record
- 11 Mar 2015 This trial is expected to be initiated in the first half of 2016, according to a Bellicum Pharmaceuticals media release.